Compare BGLC & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGLC | PULM |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 9.4M |
| IPO Year | 2019 | 2013 |
| Metric | BGLC | PULM |
|---|---|---|
| Price | $2.32 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.8K | ★ 74.5K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 45.78 | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,510,646.00 | $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $0.23 | $1.32 |
| 52 Week High | $15.19 | $9.37 |
| Indicator | BGLC | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 27.61 |
| Support Level | $2.12 | N/A |
| Resistance Level | $2.73 | $4.97 |
| Average True Range (ATR) | 0.11 | 0.15 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 34.31 | 1.57 |
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).